|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||21.83 - 22.76|
|52-week range||21.83 - 22.76|
|Beta (5Y monthly)||0.82|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The biopharma outfit has put some red flags in the rearview mirror, and sees a plausible approval on the horizon.
Iovance (IOVA) is developing several TIL therapies, including LN-145, in a mid-stage study. Data from the lung cancer cohort evaluating LN-145 monotherapy demonstrates an ORR of 21.4%.
A single word defines the economic and market conversation right now: inflation.